152 related articles for article (PubMed ID: 11926629)
41. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
[TBL] [Abstract][Full Text] [Related]
42. [First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs].
Pedrós C; Cereza G; Laporte JR
Med Clin (Barc); 2002 Mar; 118(11):415-7. PubMed ID: 11943104
[TBL] [Abstract][Full Text] [Related]
43. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
Hunt RH; Bowen B; Mortensen ER; Simon TJ; James C; Cagliola A; Quan H; Bolognese JA
Am J Med; 2000 Aug; 109(3):201-6. PubMed ID: 10974182
[TBL] [Abstract][Full Text] [Related]
44. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
Hawkey CJ; Jackson L; Harper SE; Simon TJ; Mortensen E; Lines CR
Aliment Pharmacol Ther; 2001 Jan; 15(1):1-9. PubMed ID: 11136272
[TBL] [Abstract][Full Text] [Related]
45. Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry.
Jackson ID; Heidemann BH; Wilson J; Power I; Brown RD
Br J Anaesth; 2004 May; 92(5):675-80. PubMed ID: 15033894
[TBL] [Abstract][Full Text] [Related]
46. Probable rofecoxib-induced thrombocytopenia.
Kentos A; Robin V; Lambermont M; Jurdan M; Pignarelli M; Feremans W
Rheumatology (Oxford); 2003 May; 42(5):699-700. PubMed ID: 12709555
[No Abstract] [Full Text] [Related]
47. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.
Malmstrom K; Fricke JR; Kotey P; Kress B; Morrison B
Clin Ther; 2002 Oct; 24(10):1549-60. PubMed ID: 12462285
[TBL] [Abstract][Full Text] [Related]
48. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
[TBL] [Abstract][Full Text] [Related]
49. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
50. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children.
Kidon MI; Kang LW; Chin CW; Hoon LS; See Y; Goh A; Lin JT; Chay OM
Pediatrics; 2005 Nov; 116(5):e675-80. PubMed ID: 16230465
[TBL] [Abstract][Full Text] [Related]
51. Management of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactions.
Saff RR; Banerji A
Allergy Asthma Proc; 2015; 36(1):34-9. PubMed ID: 25562554
[TBL] [Abstract][Full Text] [Related]
52. Effect of a selective nonsteroidal anti-inflammatory inhibitor of cyclooxygenase-2 on the small bowel of rats.
Leite AZ; Sipahi AM; Damião AO; Garcez AT; Buchpiguel CA; Lopasso FP; Lordello ML; Agostinho CL; Laudanna AA
Braz J Med Biol Res; 2004 Mar; 37(3):333-6. PubMed ID: 15060699
[TBL] [Abstract][Full Text] [Related]
53. Rofecoxib.
Hillson JL; Furst DE
Expert Opin Pharmacother; 2000 Jul; 1(5):1053-66. PubMed ID: 11249495
[TBL] [Abstract][Full Text] [Related]
54. Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Çelik GE; Erkekol FÖ; Aydın Ö; Demirel YS; Mısırlıgil Z
Allergol Immunopathol (Madr); 2013; 41(3):181-8. PubMed ID: 23031659
[TBL] [Abstract][Full Text] [Related]
55. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Harley C; Wagner S
Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
[TBL] [Abstract][Full Text] [Related]
56. Avoidance of nonsteroidal anti-inflammatory drugs after negative provocation tests in urticaria/angioedema reactions: Real-world experience.
Bommarito L; Zisa G; Riccobono F; Villa E; D'Antonio C; Calamari AM; Poppa M; Moschella A; Di Pietrantonj C; Galimberti M
Allergy Asthma Proc; 2014; 35(4):303-6. PubMed ID: 24992549
[TBL] [Abstract][Full Text] [Related]
57. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
Ray WA; Stein CM; Daugherty JR; Hall K; Arbogast PG; Griffin MR
Lancet; 2002 Oct; 360(9339):1071-3. PubMed ID: 12383990
[TBL] [Abstract][Full Text] [Related]
58. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
Mamdani M; Rochon PA; Juurlink DN; Kopp A; Anderson GM; Naglie G; Austin PC; Laupacis A
BMJ; 2002 Sep; 325(7365):624. PubMed ID: 12242172
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty.
Reuben SS; Fingeroth R; Krushell R; Maciolek H
J Arthroplasty; 2002 Jan; 17(1):26-31. PubMed ID: 11805921
[TBL] [Abstract][Full Text] [Related]
60. Cutaneous reactions to non-steroidal anti-inflammatory drugs.
Kasemsarn P; Kulthanan K; Tuchinda P; Dhana N; Jongjarearnprasert K
J Drugs Dermatol; 2011 Oct; 10(10):1160-7. PubMed ID: 21968666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
